Bayer: Earnings forecast revised in the face of economic downturn
This reassessment has been prompted mainly by a sharp drop in earnings from the biotechnology product Kogenate, combined with the current weakness of the economy and muted prospects for the remainder of the year. Another factor is that raw material costs have not gone down as much as expected.
The weakness of the U.S. economy has caused growth to slow in Europe and Asia as well. This has harmed the business of the Polymers segment in particular, where weak demand has prevented the company from raising selling prices enough to offset high raw material costs.
The Health Care segment is being greatly hampered in the current quarter by the production problems for Kogenate. Very good business in the other, chemically produced pharmaceutical products does not compensate for this effect. For this reason the segment's full-year earnings currently are not expected to match the 2000 level.
The Chemicals and Agriculture business segments, however, are showing an upward trend, with Chemicals – particularly the specialties – continuing the strong performance of the first quarter.
The same applies in the Agriculture segment, where business increased in April and May as anticipated. Bayer expects full-year results for this segment to be on target.
Despite the economic slowdown, Bayer will adhere to its budgets for both capital spending and R&D, underlining the company's growth ambitions for the coming years.
Most read news
Organizations
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.